



#19 TECH CEN
PTO SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0053
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
SEP 09 2002
RECEIVED
6002900

Please type or plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

Application Number	09/847,936
Filing Date	May 3, 2001
First Named Inventor	H. Kirk HAMMOND
Group Art Unit	1646
Examiner Name	To Be Assigned
Total Number Of Pages In This Submission	26 pages + 47 refs
Attorney Docket No.	220002057125

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none"> • Form PTO-1449 + copy - 22 pages • Forty-seven (47) references • Return receipt postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 Catherine M. Polizzi, Registration No. 40,130
Signature	
Date	September 6, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 6, 2002.

Kathy Farrell

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

BEST AVAILABLE COPY



PATENT
Docket No. 220002057215
Client Ref. 94-1619

RECEIVED
TECH CENTER 1600/2000
SEP 10 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on September 6, 2002.

Kathy Farrell
Kathy Farrell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

H. Kirk HAMMOND et al.

Serial No.: 09/847,936

Filing Date: May 3, 2001

For: TECHNIQUES AND COMPOSITIONS
FOR TREATING CARDIOVASCULAR
DISEASE BY IN VIVO GENE
DELIVERY

Examiner: To Be Assigned

Group Art Unit: 1646

#19
MJD
2/26/03

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents numbered 49-59 and 172-207 are also submitted herewith. The documents numbered 1-10, 21-45 and 60-150 were previously submitted in an Information Disclosure Statement directed to the related application Serial Number 09/021,773, filed February 11, 1998, and the documents numbered 11-20 and 151-171 were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/132,167, filed August 10, 1998, and, accordingly, copies are not included herewith.

This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

Please note, the documents numbered 46, 47 and 48 correspond to the PCT application documents numbered 27, 56 and 27 respectively.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220002057125. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 6, 2002

Respectfully submitted,

By: 
Catherine M. Polizzi
Registration No. 40,130

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5651
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 220002057125	Application Number 09/847,936
		Applicant	H. Kirk HAMMOND et al.
		Filing Date May 3, 2001	Group Art Unit 1646
		Mailing Date September 6, 2002	

RECEIVED
TECH CENTER 1600/2000
SEP 10 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/10/1991	5,071,962	Morrison et al.			
	2.	11/23/1993	5,264,618	Felgner et al.			
	3.	02/01/1994	5,283,185	Epand et al.			
	4.	07/12/1994	5,328,470	Nabel et al.			
	5.	08/02/1994	5,334,761	Gebeyehu et al.			
	6.	09/13/1994	5,346,812	Voellmy et al.			
	7.	09/20/1994	5,348,945	Berberian et al.			
	8.	08/22/1995	5,443,836	Downey et al.			
	9.	11/17/1995	5,459,127	Felgner			
	10.	08/11/1998	5,792,453	Hammond et al.			
	11.	07/18/1994	5,586,982	Abela			
	12.	07/29/1997	5,652,225	Isner			
	13.	08/26/1997	5,661,133	Leiden et al.			
	14.	06/01/1999	5,661,133	Leiden et al.			
	15.	09/30/1997	5,672,344	Kelley et al.			
	16.	12/16/1997	5,698,531	Nabel et al.			
	17.	01/13/1998	5,707,969	Nabel et al.			
	18.	08/25/1998	5,797,870	March et al.			
	19.	12/22/1998	5,851,806	Koveski et al.			
	20.	11/30/1999	5,994,106	Koveski et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	21.	05/16/1991	WO 91/06309	WIPO			
	22.	11/14/1991	WO 91/17424	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600/2500
NOV 10 2002

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

SEP 09 2002

PARENT & TRADEMARK OFFICE

Docket Number 220002057125	Application Number 09/841,936
Applicant	H. Kirk HAMMOND et al.
Filing Date May 3, 2001	Group Art Unit 1646
Mailing Date September 6, 2002	


23.	05/29/1992	WO 92/08796	WIPO				
24.	04/01/1993	WO 93/06223	WIPO				Abstract
25.	10/14/1993	WO 93/19768	WIPO				
26.	12/23/1993	WO 93/25673	WIPO				
27.	05/26/1994	WO 94/11506	WIPO				
28.	11/24/1994	WO 94/26914	WIPO				
29.	12/08/1994	WO 94/28143	WIPO				
30.	01/05/1995	WO 95/00655	WIPO				
31.	01/26/1995	WO 95/02697	WIPO				
32.	01/26/1995	WO 95/02698	WIPO				
33.	05/18/1995	WO 95/13365	WIPO				
34.	05/18/1995	WO 95/13392	WIPO				
35.	06/22/1995	WO 95/16772	WIPO				
36.	06/29/1995	WO 95/17373	WIPO				
37.	09/08/1995	WO 95/23867	WIPO				Abstract
38.	10/12/1995	WO 95/27071	WIPO				
39.	09/28/1995	WO 95/25803	WIPO				Abstract
40.	10/05/1995	WO 95/26409	WIPO				Abstract
41.	10/26/1995	WO 95/28494	WIPO				
42.	01/25/1996	WO 96/01840	WIPO				
43.	06/13/1996	WO 96/17947	WIPO				
44.	12/19/1996	WO 96/39830	WIPO				
45.	03/12/1998	WO 98/10085	WIPO				
46.	04/27/1993	27902/92	Australia (WO 94/11506 counterpart)				
47.	10/08/1998	94495/98	Australia (WO 99/17807 counterpart)				
48.	05/18/1995	2,149,771	Canada (WO 94/11506 counterpart)				
49.	03/21/1996	28533/95	Australia				
50.	12/21/1995	WO 95/34671	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 220002057125	Application Number 09/847,936
				Applicant	H. Kirk HAMMOND et al.
				Filing Date May 3, 2001	Group Art Unit 1646
				Mailing Date September 6, 2002	



RECEIVED
U.S. PATENT & TRADEMARK OFFICE
SEP 10 2002
TECH CENTER 1600/2900

51.	09/06/1996	WO 96/26742	WIPO			
52.	10/03/1996	WO 96/30535	WIPO			
53.	12/19/1996	WO 96/40195	WIPO			
54.	07/30/1998	WO 98/32859	WIPO			
55.	11/12/1998	WO 98/50079	WIPO			
56.	04/15/1999	WO 99/17807	WIPO			
57.	04/22/1999	WO 99/18792	WIPO			
58.	08/19/1999	WO 99/40945	WIPO			
59.	07/06/2000	WO 00/38518	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	60.	Altura B.M. and Halevy S., "Cardiovascular actions of histamine," In: Histamine II and Anti-Histaminics: Chemistry, Metabolism and Physiological and Pharmacological Actions (Rocha e Silva M, ed) Handbuch der Experimentellen Pharmakologie, Vol 18, Part 2. Springer Verlag, Berlin, Chapter 1 pp 1-39 (1978)
	61.	Banai et al. "Angiogenic-Induced Enhancement of Collateral Blood Flow to Ischemic Myocardium by Vascular Endothelial Growth Factor in Dogs," Circulation Vol. 89:2183-2189 (1994)
	62.	Barr et al., "PCGT Catheter-Based Gene Transfer Into the Heart Using Replication-Deficient Recombinant Adenoviruses," Journal of Cellular Biochemistry, Supplement 17D pg. 195, Abstract P101 (March 1993)
	63.	Barr et al., "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," Gene Therapy, Vol.1:51-58 (1994)
	64.	Barr et al., "Induction of Angiogenesis following In Vivo Gene Transfer into Myocardium," Supplement II, Circulation, Vol. 84(4):Abstract 1673 (1991)
.	65.	Barr et al., "Somatic Gene Therapy for Cardiovascular Disease," TCM, Vol. 4(2):57-63 (1994)
	66.	Berns, "Chapter 62: Parvoviridae and Their Replication," in Virology, pp. 1743-1763 (Raven Press 1990)
	67.	Brigham et al., "Cationic Liposomes and DNA Delivery," J. Liposome Res., Vol. 3(1): 31-49 (1993)
	68.	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins," Annu. Rev. Biochem, Vol. 58:575-606 (1989)
	69.	Burgess, "Structure-Function Studies of Acidic Fibroblast Growth Factor," Ann. N.Y. Acad. Sci., Vol. 638: 89-97 (1991)
	70.	Burns et al., "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)



SEP 09 2002
PATENT & TRADEMARK OFFICE

Docket Number 220002057125	Application Number 09/844,936
Applicant	H. Kirk HAMMOND et al.
Filing Date May 3, 2001	Group Art Unit 1046
Mailing Date September 6, 2002	

	to very high titer and efficient gene transfer into mammalian and nonmammalian cells," Proc Natl Acad Sci (USA), Vol 90:8033-8037 (1993)
71.	Carter, B., "AAV DNA Replication, Integration, and Genetics," in CRC Handbook of Parvoviruses, edited by Tijssen P., Vol. I, pp. 169-226 (1990)
72.	Carter, B., "Adeno-associated virus vectors," Curr. Opin. Biotechnol., Vol. 3: 533-539 (1992)
73.	Chatterjee et al., "Strategies for Efficient Gene Transfer into Hematopoietic Cells," Ann. NY Acad. Sci., Vol. 770:79-90 (1995)
74.	Chonn et al., "Recent advances in liposomal drug-delivery systems," Curr. Opin. in Biotech. Vol. 6: 698-708 (1995)
75.	Curiel et al., "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," Human Gene Therapy Vol. 3:147-154 (1992)
76.	Du et al., "Efficient transduction of human neurons with an adeno-associated virus vector," Gene Therapy Vol. 3: 254-261 (1996)
77.	Feng et al., "Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector," Nature Biotechnology, Vol. 15: 866-870 (1997)
78.	Flotte et al., "Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells," Am. J. Respir. Cell Mol. Biol. Vol. 7:349-356 (1992)
79.	Flotte et al., "Adeno-associated virus vectors for gene therapy," Gene Therapy Vol. 2:357-362 (1995)
80.	Flugelman, Moshe Y., "Inhibition of Intravascular Thrombosis and Vascular Smooth Muscle Cell Proliferation by Gene Therapy," Thromb. Haemostasis, Vol. 74(1):406-410 (1995)
81.	Franz et al., "Characterization of a Cardiac-Selective and Developmentally Upregulated Promoter in Transgenic Mice," Cadioscience, Vol. 5(4):235-243 (1994)
82.	Franz et al., "Heart-Specific Targeting of Firefly Luciferase by the Myosin Light Chain-2 Promoter and Developmental Regulation in Transgenic Mice," Circulation Research, Vol. 73(4):629-638 (1993)
83.	French et al., "Direct In Vivo Gene Transfer Into Porcine Myocardium Using Replication-Deficient Adenoviral Vectors," Circulation, Vol. 90(5):2414-2424 (1994)
84.	French et al., "Feasibility and Limitations of Direct In Vivo Gene Transfer Into Porcine Myocardium Using Replication-Deficient Adenoviral Vectors," Circulation, Vol. 90:I-517 Abstract No. 2785 (1994)
85.	French et al., "Gene Transfer and cardiovascular disorders," Herz, Vol. 18(4):222-229 (1993)
86.	French et al., "Percutaneous Transluminal In Vivo Gene Transfer by Recombinant Adenovirus in Normal Porcine Coronary Arteries, Atherosclerotic Arteries, and Two Models of Coronary Restenosis," Circulation, Vol. 90(5):2402-2413 (1994)
87.	Garrison JC., "Autacoids; Drug Therapy of Inflammation," in Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th Ed: Gilman AG, Rall TW, Nies AS, Taylor P, eds)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

SEP 09 2002

Docket Number 220002057125

Application Number 10/847,936

Applicant

H. Kirk HAMMOND et al.

Filing Date May 3, 2001

Group Art Unit 1646

Mailing Date September 6, 2002

TECH CENTER 1600 SEP 10 2002 RECEIVED
1600 2000

	Pergamon Press, pp 574-599(1990)
88.	Giordano et al., "Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart," Nature Medicine, Vol. 2(5):534-539 (1996)
89.	Giordano et al. "Adenovirus-Mediated Gene Transfer Reconstitutes Depressed Sarcoplasmic Reticulum Ca ²⁺ -ATPase Levels and Shortens Prolonged Cardiac Myocyte Ca ⁺ Transients," Circulation, Vol. 96(2):400-403 (1997)
90.	Giordano et al., "Adenoviral Based In-Vivo Gene Transfer in the Pig," Clin. Res., Vol. 42:123A (1994)
91.	Giordano et al., "Reduced Myocardial Ischemia After Recombinant Adenovirus Mediated In-Vivo Fibroblast Growth Factor-5 Gene Transfer," J. Investigative Med., Supplement 2, Vol. 43:287A (1995)
92.	Goldsmith, M.F., "Tomorrow's Gene Therapy Suggests Plenteous, Patent Cardiac Vessels," JAMA, Vol. 268(23):3285-3286 (1992)
93.	Gomez-Foix et al., "Adenovirus-mediated Transfer of the Muscle Glycogen Phosphorylase Gene into Hepatocytes Confers Altered Regulation of Glycogen Metabolism," J. Biological Chemistry, Vol. 267(35):25129-25134 (1992)
94.	Graham et al., "Chapter 11: Manipulation of Adenovirus Vectors," in Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols, Murray, E. (ed.), Humana Press, Clifton, N.J. pp. 109-128 (1991)
95.	Guzman et al., "Efficient Gene Transfer Into Myocardium by Direct Injection of Adenovirus Vectors," Circulation Research, Vol. 73(6):1202-1207 (1993)
96.	Hammond et al. "Effects of Dobutamine and Arbutamine on Regional Myocardial Function in a Porcine Model of Myocardial Ischemia," J. Am. Coll. Cardiol., Vol. 23(2):475-482 (1994)
97.	Hammond et al. "Regional Myocardial Downregulation of the Inhibitory Guanosine Triphosphate-binding Protein (G _i α ₂) and β -Adrenergic Receptors in a Porcine Model of Chronic Episodic Myocardial Ischemia," J Clin Invest, Vol. 92:2644-2652 (1993)
98.	Harada et al., "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts," J Clin Invest, Vol. 94:623-630 (1994)
99.	Horwitz, M.S., Adenoviridae and Their Replication, in Fields Virology Vol. 2, Fields, B., et al. (eds.), Raven Press New York, pp. 1679-1721 (1990)
100.	Kass-Eisler et al., "Quantitative Determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo," Proc. Natl. Acad. Sci. USA , Vol. 90:11498-11502 (1993)
101.	Kitaoka et al., "Distribution of FGF-5 in the Rhesus Macaque Retina," Invest. Ophthalmol. Vis. Sci., Vol. 35(8):3189-98 (1994)
102.	Klagsbrun et al., "The Fibroblast Growth Factor Family: Structural and Biological Properties," Progress in Growth Factor Research, Vol. 1:207-235 (1989).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 220002057125	Application Number 09/847,926
		Applicant	H. Kirk HAMMOND et al.
		Filing Date May 3, 2001	Group Art Unit 1646
		Mailing Date September 6, 2002	

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
SEP 09 2002
10 2002
160012900

103.	Kotin, R., "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," Human Gene Therapy, Vol. 5: 793-801 (1994)
104.	Kurabayashi et al., "Functional Identification of the Transcriptional Regulatory Elements within the Promoter Region of the Human Ventricular Myosin Alkali Light Chain Gene," J. Biol. Chem., Vol. 265(31):19271-19278 (1990)
105.	Lai et al., "A Rapid Method for Screening Vaccinia Virus Recombinants," Biotechniques, Vol. 10(5):564-565 (1991)
106.	Ledley, FD, "Nonviral Gene Therapy: The Promis of Genes as Pharmaceutical Products," Human Gene Therapy Vol. 6: 1129-1144 (1995)
107.	Lee et al. "Myosin Light Chain-2 Luciferase Transgenic Mice Reveal Distinct Regulatory Programs for Cardiac and Skeletal Muscle-specific Expression of a Single Contractile Portein Gene," J Biol Chem Vol. 267:15875-15885 (1992)
108.	Lee et al., "Functional Analysis of the Endothelin-1 Gene Promoter," J Biol Chem Vol. 265:10446-10450 (1990)
109.	LeMarchand et al., "Adenovirus-Mediated Transfer and Expression of Exogenous Genes to Human Endothelial Cells in Intact Human Blood Vessels <i>Ex Vivo</i> ," Clinical Research, Vol. 40(2):226A (1992)
110.	Marber, M.S., et al., "Overexpression of the Rat Inducible 70-kD Heat Stress Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury," J. Clin. Invest., Vol. 95:1446-1456 (1995)
111.	Marshall et al., "Gene Therapy's Growing Pains," Science, Vol. 269:1050-1055 (1995)
112.	Mazur et al., "Coronary Restenosis and Gene Therapy," Texas Heart Institute Journal, Vol. 21:104-111 (1994)
113.	McDonald, P., et al., "Models of Gene Therapy for Myocardial Ischemia," J. Cell. Biochem. Supp., Vol. 21A:381, Abstract No. C6-225 (1995)
114.	McGrory, "A Simple Technique for the Rescue of Early Region I Mutations into Infectious Human Adenovirus Type 5," Virology, Vol. 163:614-617 (1988)
115.	Miller et al., "Targeted vectors for gene therapy," FASEB Journal 9: 190-199 (1995)
116.	Muhlhauser et al., "In Vivo Angiogenesis Induced by Recombinant Adenovirus Vectors Coding Either for Secreted or Nonsecreted Forms of Acidic Fibroblast Growth Factor," Human Gene Therapy, Vol. 6:1457-1465 (1995)
117.	Muhlhauser et al., "VEGF ₁₆₅ Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," Circulation Research, Vol. 77(6):1077-1086 (1995)
118.	Muzyczka, N., "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," in Current Topics in Microbiology and Immunology, Vol.158: 97-129 (1992)
119.	Nabel et al., "Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
SEP 09 2002
10 2002
160012900

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 220002057125	Application Number 09/847,936
		Applicant	H. Kirk HAMMOND et al.
		Filing Date May 3, 2001	Group Art Unit 1646
		Mailing Date September 6, 2002	
		in arteries <i>in vivo</i> ," Nature, Vol. 362:844-846 (1993)	
	120.	Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (December 7, 1995)	
	121.	Pasamontes et al., "Direct identification of recombinant vaccinia virus plaques by PCR," J. Virol. Methods, Vol. 35:137-141 (1991)	
	122.	Pili et al., "Adenovirus-mediate gene transfer of angiogenic growth factors and biosafety: Lack of increase tumorigenicity <i>In Vivo</i> ," Circulation, Vol. 90(4):328 abstract (1994)	
	123.	Pili et al., "Angiogenesis induced by adenovirus-mediated gene transfer of secreted and non-secreted forms of acidic fibroblast growth factor," Circulation, Vol. 90(4) Abstract 2777 (1994)	
	124.	Pili et al., Adenovirus-mediated Gene Transfer into Vascular Endothelial Cells of Recombinant Secreted and Non-Secreted Forms of Acidic Fibroblast Growth Factor," J. of Cellular Biochemistry, Supplement 18A, pg. 328 Abstract EZ310 (Jan. 1994)	
	125.	Plumier et al., "Transgenic Mice Expressing the Human Heat Shock Protein 70 Have Improved Post-Ischemic Myocardial Recovery," J. Clin. Invest., Vol. 95:1854-1860 (1995)	
	126.	Poole et al., "Analysis of capillary geometry in rat subepicardium and subendocardium," Am J Physiol, Vol. 28(1):H204-H210 (1990)	
	127.	Remington's Pharmaceuticals Sciences by E.W. Martin (13th edition)	
	128.	Roth et al. Development of coronary collateral circulation in left circumflex Ameroid-occluded swine myocardium," Am J Physiol, Vol. 253:H1279-1288 (1987)	
	129.	Roth et al. "Downregulation of Cardiac Guanosine 5'-Triphosphate-binding Proteins in Right Atrium and Left Ventricle in Pacing-induced Congestive Heart Failure," J Clin Invest 91:939-949 (1993)	
	130.	Roth et al. "Effect of Long-term Exercise on Regional Myocardial Function and Coronary Collateral Development After Gradual Coronary Artery Occlusion in Pigs," Circulation Vol. 82:1778-1789 (1990)	
	131.	Sahn et al. "Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements," Circulation Vol. 58(6):1072-1083 (1978)	
	132.	Schneider and French, "The Advent of Adenovirus: Gene Therapy for Cardiovascular Disease," Circulation Vol. 88:1937-1942 (1993)	
	133.	Schofield et al., "Non-Viral Approaches to Gene Therapy," British Med. Bull. Vol. 51(1): 56-71 (1995)	
	134.	Schreier, H., "The new frontier: gene and oligonucleotide therapy," Pharmaceutica Acta Helveticae 68: 145-159 (1994)	
	135.	Seddon et al. "Structure/Activity Relationships in Basic FGF," Ann. N.Y. Acad. Sci. Vol. 638:98-108 (1991)	
	136.	Skyba et al. "Quantification of Myocardial Perfusion with Myocardial Contrast Echocardiography During Left Atrial Injection of Contrast," Circulation Vol. 90:1513-1521 (1994)	
	137.	Solodin et al., "A Novel Series of Amphiphilic Imidazolinium Compounds for in Vitro and in Vivo	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			


RECEIVED
TECH CENTER 1600/2000
10/2002

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

SEP 09 2002

(Use several sheets if necessary)



Docket Number 220002057125	Application Number 09/112,936
Applicant	H. Kirk HAMMOND et al.
Filing Date May 3, 2001	Group Art Unit 1646
Mailing Date September 6, 2002	

	Gene Delivery," Biochemistry 34: 13537-13544 (1995)
138.	Stratford-Perricaudet et al., "Widespread Long-Term Gene Transfer to Mouse Skeletal Muscles and Heart," Vol. 90(2):626-630 (1992)
139.	Taira et al. "cDNA Sequence of Human Transforming Gene hst and Identification of the Coding Sequence Required for Transforming Activity," Proc. Natl. Acad. Sci. USA Vol. 84:2980-2984 (1987)
140.	Thompson et al., "Heparin-binding growth factor 1 induces the formation of organoid neovascular structures <i>in vivo</i> ," PNAS, Vol. 86:7928-7932 (1989)
141.	Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor," J. Biol. Chem., Vol. 266(18):11947-11954 (1991)
142.	Unger et al., "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model," Am J Physiol, Vol 266:H1588-H1595 (1994)
143.	Vile et al., "A marriage of viral vectors," Nature Biotechnology, 15: 840-841 (1997)
144.	Wang, Y.J. and Hanson, M.A. "Parental Formulations of Proteins and Peptides: Stability and Stabilizers," Journals of Parental Sciences and Technology, Technical Report No. 10, Supp. 42:S4-S26 (1988)
145.	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," Am. J. Med. Science., Vol. 306(2):129-136 (1993)
146.	White et al., "Coronary Collateral Development in Swine After Coronary Artery Occlusion," Circ. Res., Vol. 71:1490-1500 (1992)
147.	Yanagisawa-Miwa et al., "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor," Science, Vol. 257:1401-1403 (1992)
148.	Yang et al. "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy" Proc. Natl. Acad. Sci. (U.S.A.) Vol. 91(10):4407-11 (1994)
149.	Zhan et al., "The Human FGF-5 Oncogene Encodes a Novel Protein Related to Fibroblast Growth Factors," Mol. Cell. Biol., Vol. 8(8):3487-3495 (1988)
150.	Zhang et al., "Generation and Identification of Recombinant Adenovirus by Liposome-Mediated Transfection and PCR Analysis," BioTechniques, Vol. 15(5):868,870-872 (1993)
151.	Anderson, W.F. (1998). "Human Gene Therapy," Nature 392(Supp):25-30.
152.	Blau et al. (1995). "Molecular Medicine Gene Therapy - A Novel Form of Drug Delivery," New England Journal of Medicine 333:1204-1207.
153.	Crystal, R.G. (1995). "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science 270:404-410.
154.	Feldman et al., "Low Efficiency of Percutaneous Adenovirus-mediated Arterial Gene Transfer in the Atherosclerotic Rabbit," J. Clin. Invest., 95:2662-2671 (1995).

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 220002057125	Application Number 09/847936
		Applicant	H. Kirk HAMMOND et al.
		Filing Date May 3, 2001	Group Art Unit 1646
		Mailing Date September 6, 2002	

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
SEP 09 2002
10 2002
TECH CENTER 1600/2000

155.	Flugelman <i>et al.</i> "Low Level In Vivo Gene Transfer Into the Arterial Wall Through a Perforated Balloon Catheter", <i>Circulation</i> , 85(3):1110-7 (1992).
156.	Friedman, (1997) <i>Scientific American</i> 96-101
157.	Helmer <i>et al.</i> , "Regional Deficits of Myocardial Blood Flow and Function in Left Ventricular Pacing-Induced Heart Failure", <i>Circulation</i> , 94(9):2260-2267 (1996).
158.	Lazarous <i>et al.</i> , (1996) <i>Circulation</i> 94:1074-1082.
159.	Lin <i>et al.</i> , "Expression of Recombinant Genes in Myocardium In Vivo After Direct Injection of DNA", <i>Circulation</i> , 82:2217-2221 (1990).
160.	Miller <i>et al.</i> (1995). "Targetid Vectors for Gene Therapy," <i>FASEB J.</i> 9:190-199.
161.	Morgan, <i>et al.</i> (1993). "Human Gene Therapy," <i>Ann. Review Biochem</i> 62:191-271.
162.	Nabel <i>et al.</i> , "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", <i>Science</i> , 244:1342-1344 (1989).
163.	Nabel <i>et al.</i> , "Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall", <i>Science</i> , 249:1285-1288 (1990).
164.	Plautz <i>et al.</i> , "Direct Gene Transfer for the Understanding and Treatment of Human Disease", <i>Annals New York Academy of Sciences</i> , 16:144-153 (1994).
165.	Rome <i>et al.</i> , "Anatomic Barriers Influence the Distribution of In Vivo Gene Transfer Into the Arterial Wall", <i>Arteriosclerosis and Thrombosis</i> , 14(1):148-161 (1994).
166.	Rome <i>et al.</i> , "Adenoviral Vector-Mediated Gene Transfer into Sheep Arteries Using a Double-Balloon Catheter", <i>Human Gene Therapy</i> , 5:1249-1258 (1994).
167.	Ross <i>et al.</i> (1996). "Gene Therapy in the United States: A Five - Year Status Report," <i>Human Gene Therapy</i> 7:1781-1790.
168.	Rowland, R.T. <i>et al.</i> , (September 1995) "Potential gene therapy strategies in the treatment of cardiovascular disease" <i>Am. Thorac. Surg.</i> 60(3):721-728.
169.	Steg <i>et al.</i> , "Arterial Gene Transfer to Rabbit Endothelial and Smooth Muscle Cells Using Percutaneous Delivery of an Adenoviral Vector", <i>Circulation</i> , 90(4):1648-1656 (1994).
170.	Stratford-Perricaudet, <i>et al.</i> (1991). "Gene Transfer into Animals: The Promise of Adenovirus," <i>Human Gene Transfer</i> 219:51-61.
171.	Verma <i>et al.</i> (1997). "Gene Therapy - Promises, Problems and Prospects," <i>Nature</i> 389:239-242.
172.	Babiss, L.E. <i>et al.</i> (1987). "Cellular Promoters Incorporated into the Adenovirus Genome. Effect of Viral DNA Replication on Endogenous and Exogenous Gene Transcription," <i>J. Mol. Biol.</i> 193:643-650.
173.	Bellosta <i>et al.</i> , "Cleavage of K-FGF Produces a Truncated Molecule with Increased Biological Activity and Receptor Binding Affinity" <i>J. Cell. Biol.</i> 121(3):705-713 (1993).

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

TECH 10
PTO/SB/08 (2-92)
Sheet 10 of 10

RECEIVED
SEP 09 2002
PATENT & TRADEMARK OFFICE
1600 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20591-0000

Form PTO-1449		Docket Number 220002057125	Application Number 09/847,936
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant H. Kirk HAMMOND et al.	
		Filing Date May 3, 2001	Group Art Unit 1646
		Mailing Date September 6, 2002	
174.	Boyle, M. et al., "Limitation of Infarct Expansion and Ventricular Remodeling by Late Reperfusion" <i>Circulation</i> 88(6):2872-2883 (1993).		
175.	Buttrick, P.M. et al. (1992). "Behaviour of Genes Directly Injected into the Rat Heart in vivo," <i>Circulation Research</i> 70:193-198.		
176.	Cohn, J., "Critical Review of Heart Failure: The Role of Left Ventricular Remodeling in the Therapeutic Response" <i>Clin. Cardiol.</i> 18(Suppl. IV):12 (1995).		
177.	Dell Bovi et al., "An Oncogene Isolated by Transfection of Kaposi's Sarcoma DNA Encodes a Growth Factor That is a Member of the FGF Family" <i>Cell</i> 50:729-737 (1987).		
178.	Donath et al. (1999). "Insulin-Like Growth Factor I: An Attractive Option for Chronic Heart Failure?" <i>Drugs Aging</i> 15(4):251-254.		
179.	Gao, M. et al., (October 21, 1997) "Increased adrenergic signaling after adenylylcyclase type VI gene transfer in rat cardiac myocytes" Supplement to <i>Circulation</i> , 96(8):page I-294, Abstract No. 1636.		
180.	Gustavsson, C. et al., "Changed Blood Rheology in Patients With Idiopathic Dilated Cardiomyopathy" <i>Angiology</i> 45(2):107-111 (1994).		
181.	Hawker, R.J. et a. (1975). "Protein Losses During Sterilizing by Filtration," <i>Lab. Practices</i> 24:805-807, 814.		
182.	Iannello, A. et al. (1991). "Characterization of a Promoter Element Required for Transcription in Myocardial Cells," <i>J. Biological Chemistry</i> 266(5):3309-3316.		
183.	Isner, J.M. et al. (1996). "Clinical Evidence of Angiogenesis after Arterial Gene Transfer of PHVEGF165 in Patient with Ischaem Limb," <i>The Lancet</i> 348:370-374.		
184.	Kirshenbaum, L.A. et al. (1993). "Highly Efficient Gene Transfer into Adult Ventricular Myocytes by Recombinant Adenovirus," <i>J. Clin. Invest.</i> 92:381-387.		
185.	Lewis, B.S. et al. (1997). "Angiogenesis by Gene Therapy: A New Horizon for Myocardial Revascularization?", <i>Cardiovascular Research</i> 35(3):490-497.		
186.	Lim, C.S. et al. (1991). "Direct in vivo Gene Transfer into the Coronary and Peripheral Vasculatures of the Intact Dog," <i>Circulation</i> 83:2007-2011.		
187.	Mack, C.A. et al. (1998). "Salvage Angiogenesis Induced by Adenovirus-Mediated Gene Transfer of Vascular Endothelial Growth Factor Protects Against Ischemic Vascular Occlusion," <i>J. Vascular Surgery</i> , 27(4):699-709.		
188.	Maria, R. et al., "Morphological Bases for Thallium-201 Uptake in Cardiac Imaging and Correlates with Myocardial Blood Flow Distribution" <i>European Heart J.</i> 17:951-961 (1996).		
189.	McDonald, K.M., "Early Ventricular Remodeling After Myocardial Damage and its Attenuation by Converting Enzyme Inhibition" <i>Trans. Assoc. Am. Physicians</i> 103:229-235 (1990).		
190.	McDonald, Kenneth et al., "Angiotensin-Converting Enzyme Inhibition and Beta-Adrenoceptor Blockade Regress Established Ventricular Remodeling in a Canine Model of Discrete Myocardial Damage" <i>JACC</i> 24(7):1762-1768 (1994).		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002057125

Application Number 09/847,936


Applicant

H. Kirk HAMMOND et al.

Filing Date May 3, 2001

Group Art Unit 1646

Mailing Date September 6, 2002



	191.	Oh et al., "Altered Left Ventricular Remodeling With β -Adrenergic Blockade and Exercise After Coronary Reperfusion in Rats" <i>Circulation</i> 87(2):608-615 (1993).
	192.	Paramacek, M.S. et al. (1992). "Identification and Characterization of a Cardiac-Specific Transcriptional Regulatory Element in the Slow Cardiac Troponin C Gene," <i>Molecular and Cellular Biology</i> 12:1967-1976.
	193.	Parodi, Oberdan et al., "Myocardial Blood Flow Distribution in Patients With Ischemic Heart Disease or Dilated Cardiomyopathy Undergoing Heart Transplantation" <i>Circulation</i> 88(2):509-521 (1993).
	194.	Ping, P. et al. (1994). "Diverse G Protein and Beta-Adrenergic Receptor mRNA Expression in Normal and Failing Porcine Hearts," <i>Am J Physiol</i> 267(5pt.2):H2079-H2085.
	195.	Ping, P. et al., (October 15, 1995) "Over-expression of adenylylcyclase VI (AC _{V1}) increases β -adrenergic receptor-stimulated cAMP in neonatal rat cardiac myocytes" <i>Circulation</i> 92(8):page I-570, Abstract No. 2727.
	196.	Quantin, B. et al. (1992). "Adenovirus as an Expression Vector in Muscle Cells in vivo," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:2581-2584.
	197.	Rajanayagam, S. et al. (1996). "Delivery of VEGF to Ischemic Tissue Using Adenoviral-Modified Autologous Endothelial Cells," <i>Circulation</i> 94(8):646.
	198.	Rosenfield, M.A. et al. (1991). "Adenovirus-Mediated Transfer of a Recombinant α 1-Antitrypsin Gene to the Lung Epithelium in vivo," <i>Science</i> 252:431-434.
	199.	Sunnerhagen et al., "Regional Left Ventricular Wall Motion Abnormalities in Idiopathic Dilated Cardiomyopathy" <i>Am. J. Cardiol.</i> 65:364-369 (1990).
	200.	Takagishi et al. (1995). "Expression of the Histamine H1 Receptor Gene in Relation to Atherosclerosis," <i>Am. J. Path.</i> 146(4):981-988.
	201.	Tanny, G.B. et al. (1979). "Absorptive Retention of <i>Pseudomonas Diminata</i> by Membrane Filters," <i>J. Parenteral Drug Association</i> 33:40-51.
	202.	Trapnell, B.C. et al. (1994). "Gene Therapy Using Adenoviral Vectors," <i>Curr. Op. Biotechnology</i> 5:617-625.
	203.	Tripathy, S.K. (1996). "Immune Responses to Transgene-Encode Proteins Limit the Stability of Gene Expression Injection of Replication-Defective Adenovirus Vectors" <i>Nature Medicine</i> 2(5):545-550.
	204.	Turco, S. (1994). <u>Sterile Dosage Forms</u> . 4th edition. Lea and Febiger, a Waverley Company. Chapter 3 pp. 28-51.
	205.	Waltenberger, J. (1997). "Modulation of Growth Factor Action: Implications for the Treatment of Cardiovascular Diseases," <i>Circulation</i> 96(11):4083-4094.
	206.	Wang, G. et al. (1994). "Characterization of cis-Regulating Elements and trans-Activating Factors of the Rat Cardiac Troponin T. Gene," <i>J. Biol. Chem.</i> 364:30595-30603.
	207.	Zwiebel, J.A. et al. (1989). "High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral Vectors," <i>Science</i> 243(4888):220-222.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.